Evidence map›Paper›PMID 39045341›Full record

ArticleJournal of extracellular biology2024

Optimization of ultracentrifugation-based method to enhance the purity and proteomic profiling depth of plasma-derived extracellular vesicles and particles.

Zurong Wan, Jinghua Gu, Uthra Balaji, Linda Bojmar, Henrik Molina, Søren Heissel, Alexandra E Pagano, Christopher Peralta, Lee Shaashua, Dorina Ismailgeci and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of extracellular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Zurong WanDrukier Institute of Children's Health Weill Cornell Medicine New York New York USA.
Jinghua GuDrukier Institute of Children's Health Weill Cornell Medicine New York New York USA.
Uthra BalajiDrukier Institute of Children's Health Weill Cornell Medicine New York New York USA.
Linda BojmarChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Meyer Cancer Center Weill Cornell Medicine New York New York USA.
Henrik MolinaProteomics Resource Center The Rockefeller University New York New York USA.
Søren HeisselProteomics Resource Center The Rockefeller University New York New York USA.
Alexandra E PaganoProteomics Resource Center The Rockefeller University New York New York USA.
Christopher PeraltaProteomics Resource Center The Rockefeller University New York New York USA.
Lee ShaashuaChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Meyer Cancer Center Weill Cornell Medicine New York New York USA.
Dorina IsmailgeciDepartment of Medicine Memorial Sloan Kettering Cancer Center New York New York USA.
Hope K NarozniakDepartment of Medicine Memorial Sloan Kettering Cancer Center New York New York USA.
Yi SongHepatopancreatobiliary Service, Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA.
William R JarnaginHepatopancreatobiliary Service, Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA.
David P KelsenDepartment of Medicine Memorial Sloan Kettering Cancer Center New York New York USA.
Jaqueline BrombergDepartment of Medicine Memorial Sloan Kettering Cancer Center New York New York USA.
Virginia PascualDrukier Institute of Children's Health Weill Cornell Medicine New York New York USA.
Haiying ZhangChildren's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Meyer Cancer Center Weill Cornell Medicine New York New York USA.ORCID https://orcid.org/0000-0002-7158-2373

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
Principal ProjectU19AI144301 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Maria Virginia Pascual · 2019 to 2026
$9.9M
Systemic regulation of metastasisR35CA232093 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LYDEN, DAVID CHARLES · 2018 to 2024
$7.0M
Tumor-derived extracellular vesicles in the pre-metastatic niche.R01CA207983 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI Yves A DeClerck · 2017 to 2026
$5.6M
Development and application of asymmetric-flow field-flow (AF4) technology in fractionation and characterization of exosome subpopulations and novel nanoveiscles in pancreatic cancer modelR01CA218513 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jacob Geri, DAVID CHARLES LYDEN · 2017 to 2026
$4.3M
Role of N-Cadherin in Pancreatic Tumor MicroenvironmentU54CA163120 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2011 to 2015
$4.2M
Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapyU01CA224175 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, LEACH, STEVEN D · 2017 to 2021
$3.1M
Characterization and Functional Analysis of Breast Cancer Secreted Exosomes in MaU01CA169538 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BISSELL, MINA, LYDEN, DAVID CHARLES · 2012 to 2016
$2.9M
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDRU54CA163117 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI YU, HUA E · 2011 to 2015
$2.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA207983NCI NIH HHS R01 CA218513NCI NIH HHS R35 CA232093NCI NIH HHS U01 CA169538NCI NIH HHS U01 CA210240NCI NIH HHS U01 CA224175NCI NIH HHS U54 CA163117NCI NIH HHS U54 CA163120NIAID NIH HHS U19 AI144301
6 · The paper itself

Abstract

Circulating extracellular vesicles and particles (EVPs) are being investigated as potential biomarkers for early cancer detection, prognosis, and disease monitoring. However, the suboptimal purity of EVPs isolated from peripheral blood plasma has posed a challenge of in-depth analysis of the EVP proteome. Here, we compared the effectiveness of different methods for isolating EVPs from healthy donor plasma, including ultracentrifugation (UC)-based protocols, phosphatidylserine-Tim4 interaction-based affinity capture (referred to as "PS"), and several commercial kits. Modified UC methods with an additional UC washing or size exclusion chromatography step substantially improved EVP purity and enabled the detection of additional proteins via proteomic mass spectrometry, including many plasma membrane and cytoplasmic proteins involved in vesicular regulation pathways. This improved performance was reproduced in cancer patient plasma specimens, resulting in the identification of a greater number of differentially expressed EVP proteins, thus expanding the range of potential biomarker candidates. However, PS and other commercial kits did not outperform UC-based methods in improving plasma EVP purity. PS yielded abundant contaminating proteins and a biased enrichment for specific EVP subsets, thus unsuitable for proteomic profiling of plasma EVPs. Therefore, we have optimized UC-based protocols for circulating EVP isolation, which enable further in-depth proteomic analysis for biomarker discovery.

Indexed as

biomarkersearly cancer detectionextracellular vesicles and particles (EVPs)proteomics

Identifiers

PMID39045341
PMCPMC11263976

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.